Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Virtual COVID-19 2020 Conference: Rapid Audio Recap

Virtual
Hear insights from Renslow Sherer, MD, on some of the most important new data reported at the International AIDS Society’s 2020 Virtual COVID-19 Conference, with a focus on studies of investigational COVID-19 treatment strategies.
Renslow Sherer, MD
Released: August 19, 2020

In this episode, Dr. Sherer discusses results from key studies reported at the International AIDS Society’s 2020 Virtual COVID-19 Conference, including studies evaluating characteristics and predictors of COVID-19 mortality, factors associated with remdesivir clinical outcomes, the effect of hydroxychloroquine coadministration on remdesivir safety and efficacy, the effect of race/ethnicity on clinical outcomes with remdesivir, and sofosbuvir/daclatasvir plus lopinavir/ritonavir for the treatment of severe COVID-19. 

Content based on a CME program supported by an independent educational grant from Gilead Sciences.

Link to full program: https://www.clinicaloptions.com/infectious-disease/conference-coverage/covid19-2020 

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Renslow Sherer, MD

Director, International HIV Training Center
Professor of Medicine
University of Chicago
Chicago, Illinois

Renslow Sherer, MD, has no relevant conflicts of interest to report.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Download free slides from CCO reviewing the latest data and guidance on COVID-19 symptoms and the prevalence and duration of natural immunity

Ada Adimora, MD, MPH David Heymann, BA, MD, DTM&H Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Jens D. Lundgren, MD, DMSc Vikramjit Mukherjee, MD Roger Paredes, MD, PhD Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS Released: March 26, 2021

Download free slides from CCO reviewing the latest data and guidance on COVID-19 risk and management in special populations and persons with comorbidities

Ada Adimora, MD, MPH David Heymann, BA, MD, DTM&H Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Jens D. Lundgren, MD, DMSc Vikramjit Mukherjee, MD Roger Paredes, MD, PhD Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS Released: March 26, 2021

Download free slides from CCO reviewing the latest updates on COVID-19 epidemiology and emerging data on diagnosis and transmission

Ada Adimora, MD, MPH David Heymann, BA, MD, DTM&H Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Jens D. Lundgren, MD, DMSc Vikramjit Mukherjee, MD Roger Paredes, MD, PhD Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS Released: March 26, 2021

Download free slides from CCO reviewing the latest data and guidance on COVID-19 treatments, including authorized and investigational agents

Ada Adimora, MD, MPH David Heymann, BA, MD, DTM&H Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Jens D. Lundgren, MD, DMSc Vikramjit Mukherjee, MD Roger Paredes, MD, PhD Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS Released: March 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue